1 | 08:45-09:00 | 引导报告 |
在活检标本中如何正确认知HPV非相关性宫颈腺癌 |
|
||||||||||
2 | 09:00-09:20 |
讨论 |
|
|||||||||||
3 | 09:20-09:35 | 引导报告 |
雌激素受体阴性的子宫内膜癌 (ERneg-EC) |
|
||||||||||
4 | 09:35-09:55 |
讨论 |
|
|||||||||||
5 | 09:55-10:10 | 引导报告 |
卵巢癌高级别浆液性癌治疗相关分子标记检测 |
|
||||||||||
6 | 10:10-10:30 |
讨论 |
|
1 | 10:30-11:00 | 专题会发言 |
免疫检查点抑制剂再创新之路 |
|
1 | 11:00-11:05 | 论文发言 |
构建代谢评分系统预测子宫内膜癌临床结局并指导免疫治疗 |
|
||||
2 | 11:05-11:10 | 论文发言 |
Analysis of the Clinicopathological and Molecular Characteristics Associated with Risk of Lymph Node Metastasis in Endometrial Malignant Tumors |
|
||||
3 | 11:10-11:15 | 论文发言 |
西达本胺通过诱导核糖体翻译受损治疗子宫内膜癌的机制研究 |
|
||||
4 | 11:15-11:20 | 论文发言 |
Intratumor microbiome-derived butyrate facilitates progesterone resistance by inducing ferroptosis in endometrial cancer |
|
||||
5 | 11:20-11:25 | 论文发言 |
子宫内膜癌孕激素耐药的时序分子特征及逆转策略研究 |
|
||||
6 | 11:25-11:30 | 论文发言 |
肠道微生态与子宫内膜癌发生机制的相关性研究 |
|
||||
7 | 11:30-11:35 | 论文发言 |
Integration of Inflammatory and Nutritional Biomarkers with Machine Learning Enhances Prediction of Progesterone Response in Fertility-Preserving Endometrial Carcinoma Management |
|
||||
8 | 11:35-11:40 | 论文发言 |
NSMP亚型子宫内膜癌的临床病理特征及预后——一项单中心回顾性研究 |
|
||||
9 | 11:40-11:45 | 论文发言 |
基于多中心队列的早发性子宫内膜癌基因组及分子特征研究 |
|
||||
10 | 11:45-11:50 | 论文发言 |
子宫内膜癌诊断中宫腔镜应用与腹水细胞学阳性的相关性及风险因素分析 |
|
||||
11 | 11:50-12:00 |
讨论交流 |
1 | 13:00-13:30 | 专题会发言 |
免疫治疗在子宫内膜癌中的应用探索 |
|
1 | 13:30-13:38 | 引导报告 |
子宫内膜癌分子分型检测简化方案和NGS结合免疫组化方案的临床价值 |
|
||||
2 | 13:38-13:46 | 引导报告 |
多重分子特征子宫内膜癌的临床意义 |
|
||||
3 | 13:46-13:54 | 引导报告 |
侵袭性子宫内膜癌中分子分型的临床意义 |
|
||||
4 | 13:54-14:02 | 引导报告 |
分子分型对FIGO I-II期子宫内膜癌诊疗策略的影响 |
|
||||
5 | 14:02-14:10 | 引导报告 |
分子分型对晚期复发性子宫内膜癌诊疗策略的影响 |
|
||||
6 | 14:10-14:18 | 引导报告 |
分子分型对子宫内膜癌保留生育功能诊疗策略的影响 |
|
||||
7 | 14:18-15:30 |
讨论 |
1 | 15:30-16:00 | 专题会发言 |
晚期复发/转移EC二线治疗突破之旅 |
|
1 | 16:00-16:07 | 引导报告 |
FIGO 2023内膜癌分期的主要变化 |
|
||||||||||||||
2 | 16:07-16:14 | 引导报告 |
FIGO 2023中的IA3的诊断 |
|
||||||||||||||
3 | 16:14-16:21 | 引导报告 |
FIGO 2023分期临床应用面临的问题 |
|
||||||||||||||
4 | 16:21-17:00 |
讨论 |
|
1 | 17:00-17:05 | 论文发言 |
洛塞那肽联合左炔诺孕酮宫内缓释系统治疗子宫内膜非典型增生的前瞻性随机对照小样本临床研究 |
|
||||
2 | 17:05-17:10 | 论文发言 |
A open-label, multicentre, prospective clinical study evaluating niraparib monotherapy for maintenance of uterine serous carcinoma:Primary outcome update |
|
||||
3 | 17:10-17:15 | 论文发言 |
Immunotherapy and progestin therapy lead to different pathological responses and immune microenvironment as fertility-sparing strategies in MMRd endometrial cancer |
|
||||
4 | 17:15-17:20 | 论文发言 |
Ovarian involvement in fertility-sparing treatment of endometrial cancer |
|
||||
5 | 17:20-17:25 | 论文发言 |
Cell block whole slide image analysis for early endometrial cancer diagnosis in post-menopausal women |
|
||||
6 | 17:25-17:30 | 论文发言 |
IGFBP2 promotes proliferation and glycolysis of endometrial cancer by regulating PKM2/HIF-1α axis |
|
||||
7 | 17:30-17:35 | 论文发言 |
Integrating Homologous Recombination Deficiency Subtyping with TCGA Molecular Classification for Enhanced Prognostic Stratification and Personalized Therapy in Endometrial Cancer |
|
||||
8 | 17:35-17:40 | 论文发言 |
The epidemiological landscape of endometrial cancer worldwide: an analysis of current global patterns, temporal trends, and future burden |
|
||||
9 | 17:40-17:45 | 论文发言 |
MAL2 通过调节氨酰基-tRNA 生物合成促进子宫内膜癌发展 |
|
||||
10 | 17:45-17:50 | 论文发言 |
Correlation of estimated glucose disposal rate with endometrial cancer:cross‑sectional data from the National Health and Nutrition Examination Surveys (NHANES) 1999–2018 |
|
||||
11 | 17:50-18:00 |
讨论交流 |